Presgrave P, Woods R, Kefford R, Bell D, Raghavan D, Levi J
Department of Clinical Oncology, Royal North Shore Hospital of Sydney, St. Leonards, NSW, Australia.
Invest New Drugs. 1988 Sep;6(3):219-21. doi: 10.1007/BF00175402.
4'Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m2 and 40 mg/m2 respectively at 28 day intervals. All 22 patients were evaluable for response: No tumour responses occurred. Therapy was well tolerated. Mild gastrointestinal toxicity occurred in 41% of patients. Leucopenia with a wcc less than 3 x 10(9)/L occurred in 33% of patients and thrombocytopenia less than 100 x 10(9)/L in 9%. Severe marrow toxicity was rare and there appeared to be no difference in terms of toxicity between the different dose levels. DMDR appears to have no useful clinical activity in NSCLC.
4'-去甲氧基柔红霉素，一种口服活性柔红霉素类似物，被给予22例无法手术的非小细胞肺癌（NSCLC）患者。患者被分为低风险和高风险类别，分别每28天接受45mg/m²和40mg/m²的剂量。所有22例患者均可评估疗效：未出现肿瘤反应。治疗耐受性良好。41%的患者出现轻度胃肠道毒性。33%的患者出现白细胞减少，白细胞计数低于3×10⁹/L，9%的患者出现血小板减少，低于100×10⁹/L。严重骨髓毒性罕见，不同剂量水平之间在毒性方面似乎没有差异。4'-去甲氧基柔红霉素在NSCLC中似乎没有有效的临床活性。
